media – Page 54 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

59.1 billion autoimmune dual-antibody therapy market has seen international giants take action

The layout of bispecific antibodies in the field of tumors has become mature, but in the field of autoimmune diseases, the layout of bispecific antibodies is relatively small. The first batch of enlightened MNCs have begun to take action. Recently, autoimmune bispecific antibody therapy has increasingly become the focus of new drug research and development. Many pharmaceutical giants such as Johnson & Johnson, Sanofi, and Roche have chosen to deploy in the field of autoimmune bispecific antibodies, with a total of more than US$8.15 billion (approximately RMB 59.1 billion) in mergers and acquisitions and related drug transactions. The track of autoimmune bispecific antibody therapy has changed. Sanofi, Merck, and Roche: Grabbing the beachhead of CD3 bispecific antibodiesCD3 is closely related to the activation of T cells. By combining CD3 and tumor-associated antigens, it can guide and activate T cells to approach and kill tumor cells. At present, most of the ...
- Source: drugdu
- 108
- November 29, 2024
Shareholder shareholding auction will not have a significant impact! Industry analysis

On the evening of November 25th, Dezhan Health announced that the largest shareholder of the company, Shanghai Yueye Equity Investment Management Partnership Enterprise (Limited Partnership) (hereinafter referred to as “Shanghai Yueye”), has recently been ruled by the Shanghai Third Intermediate People’s Court to confirm its liquidation plan. All shares held by Shanghai Yueye in the company will be liquidated and disposed of through public auction. According to the data, Shanghai Yueye holds 414 million shares of the company’s unrestricted tradable shares, accounting for 19.13% of the company’s total share capital and 19.37% of the total share capital after excluding the number of shares in the company’s repurchase special account. There is no pledge or freezing of the shares it holds. The announcement states that the auction matters involved in this liquidation plan have not yet officially begun to be implemented. The specific arrangements and related requirements for public auctions shall ...
- Source: drugdu
- 113
- November 28, 2024
Promote the sinking of drugs for common chronic diseases to the grassroots level

Due to some chronic and common diseases, patients come to township health centers and community health service centers for treatment, but are told that ‘there is no medicine’. In response to the problem of difficult medication at the grassroots level, the National Health Commission and six other departments recently jointly issued the “Opinions on Reforming and Improving the Grassroots Drug Linkage Management Mechanism to Expand the Types of Grassroots Drugs”, striving to smooth the channels for drug connection between urban and rural areas, counties and townships, enhance the ability of grassroots drug allocation and use, and meet the basic medication needs of the masses. Expand types Make the medicine at the doorstep more comprehensive The proportion of grassroots diagnosis and treatment in China has reached 52% by 2023. However, some medical staff have previously reported that there are few types of drugs available at the grassroots level, limited space for ...
- Source: drugdu
- 101
- November 28, 2024
No need for injections! MIT scientists develop spray capsules that mimic squid inkjet technology, with the potential to revolutionize drug delivery methods

More than 300 years ago, British architect and scientist Sir Christopher Wren became interested in drug delivery, hoping to find a way to directly inject drugs or liquids into the human body. He made a simple syringe using tools such as goose feathers and metal tubes, and for the first time attempted to inject drug solution into a dog’s veins through injection. Since then, “injection” has gradually become a widely used method of drug delivery. Today, many large molecule biologics, such as recombinant insulin, monoclonal antibodies, and vaccines, are mainly injected into the human body to exert their therapeutic effects. However, the pain and trouble caused by injection are self-evident, especially when treating chronic diseases such as diabetes or cancer that require frequent medication, injection has brought considerable burden to patients’ daily life. So, in recent years, many scientists have been actively seeking innovative methods for drug delivery systems: without ...
- Source: drugdu
- 112
- November 28, 2024
BD Trading and IPO of Chinese Innovative Preparations

1. Jimu Biological License: Tian Tian Pharmaceutical ARVN001 600 million yuan On November 13th, Tian Shan Pharmaceutical and Ji Mu Biotechnology announced that Ji Mu Biotechnology has authorized Tian Shan Pharmaceutical with exclusive commercial rights for its ARVN001 (Triamcinolone Acetonide Choroidal Injection Suspension) under development in mainland China. ARVN001 uses a suprachoroidal microinjection (SCS microinjection) system ®） The patented technology will be used to treat uveitis related macular edema (UME) and other potential ophthalmic indications under development. Jimu Biotech will receive a total down payment and milestone payments of up to 85 million US dollars (approximately 600 million RMB). Previously, Jimu Biotechnology obtained the rights to develop and commercialize this therapy in the Asia Pacific region from Clearside Biomedical Inc. In July 2024, Jimu Biotechnology announced that ARVN001 achieved positive top line results in the Phase III clinical trial of UME in China. Meanwhile, research on the use of this ...
- Source: drugdu
- 92
- November 28, 2024
The world’s first HER2 bispecific antibody is approved for marketing, and BeiGene has the rights in the Asia-Pacific region

On November 20, local time, Jazz Pharmaceuticals announced that the U.S. FDA has accelerated the approval of its HER2-targeted bispecific antibody Zanidatamab (Ziihera), developed in collaboration with Zymeworks, for marketing for the treatment of patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. The press release pointed out that this is the first and only HER2 bispecific antibody approved by the FDA for HER2+ biliary tract cancer. Zanidatamab (ZW25) is a bispecific antibody based on the Zymeworks Azymetric platform that can simultaneously bind to two non-overlapping HER2 epitopes, i.e., biparatopic binding. This unique design can form multiple mechanisms of action, including dual blocking of HER2 signals, enhanced binding and removal of HER2 proteins on the cell surface, and strong antibody effector functions to enhance anti-tumor activity in patients. Previously, Zenidatumomab has been granted breakthrough therapy designation, fast track qualification, priority review qualification, orphan drug qualification, etc. ...
- Source: drugdu
- 76
- November 28, 2024
1.8 billion, the integration of two major pharmaceutical companies of “China Resources”

On November 21, China Resources Pharmaceutical issued the “Latest Information on the Proposed Internal Restructuring of its China Resources Shenghuo” announcement. China Resources Sanjiu and Kunming Pharmaceutical Group have entered into an equity transfer agreement. China Resources Sanjiu has conditionally agreed to sell, and Kunming Pharmaceutical Group has conditionally agreed to acquire 51% of the equity of China Resources Shenghuo, with a total price of 1.791 billion yuan (equivalent to approximately HK$1.938 billion). It is expected that China Resources Sanjiu will use the funds to supplement operating funds. After the internal restructuring is completed, China Resources Pharmaceutical’s interest in China Resources Shenghuo will be reduced from approximately 63.02% to 39.90%, and China Resources Shenghuo will remain a non-wholly owned subsidiary of China Resources Pharmaceutical. On the same day, China Resources Sanjiu announced that it had signed the “Equity Transfer Agreement between China Resources Sanjiu Pharmaceutical Co., Ltd. and Kunming Pharmaceutical ...
- Source: drugdu
- 76
- November 28, 2024
Huadong Medicine’s “GLP-1R/GCGR/FGF21R triple agonist” was approved for new clinical trials

On November 15, according to the official website of CDE, the Class 1 new drug DR10624 injection of Huadong Medicine’s subsidiary Daoer Biotechnology has obtained implicit approval for clinical trials, and its indications are metabolic-related fatty liver disease/metabolic-related fatty hepatitis. According to public information, the drug is a GLP-1R/GCGR/FGF21R triple agonist. DR10624 is a chimeric peptide segment targeting GLP1R/GCGR at the N-terminus, fused to an engineered IgG1 Fc, and a recombinant FGF21 mutant is fused to the C-terminus of the Fc. Preclinical study results show that DR10624 has strong metabolic regulation and improved efficacy. Huadong Medicine mentioned in the announcement that DR10624 is a symmetrical dimer in structure. While having the biological activity of GLP-1R, GCGR, and FGF21R triple agonists, it can also be fused with a deglycosylated IgG1 Fc to extend the half-life. In April 2022, Doer Biopharma was approved to conduct a Phase I clinical trial of DR10624 ...
- Source: drugdu
- 109
- November 28, 2024
“Innovative Cardiac Tissue Ablation Clip” approved by CE

AtriCure, a leading company in the treatment of atrial fibrillation, announced today that its EnCompass cardiac tissue ablation clip has received the EU CE mark, meaning the device can be sold in more than 30 countries in the European Economic Area (EEA). A number of innovative products were launched AtriCure was founded in 2000 and focuses on cardiac surgery solutions. The company mainly produces and sells cardiac ablation devices, providing innovative technologies for the treatment of atrial fibrillation and related diseases. At present, AtriCure has 138 authorized patents in the United States and has served more than 300,000 patients with atrial fibrillation since 2004. It is understood that the EnCompass cardiac tissue ablation clamp is used for cardiac tissue ablation surgery, including comprehensive epicardial ablation of the left atrium during open heart surgery. This is a simpler and faster method of open-chest cardiac ablation, allowing doctors to perform comprehensive epicardial ...
- Source: drugdu
- 111
- November 28, 2024
HOSPITALAR

Organiser：Informa Markets Time：May 20th – 23rd, 2025 Address： Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1.5, São Paulo – SP Exhibition hall：São Paulo Expo Product range: Medical Equipment Exhibition Area: Hospital technology facilities and equipment; medical clinic technology and equipment; ward furniture and equipment; diagnostic and treatment equipment; biochemical and testing equipment; pharmaceutical products; hygienic materials; medical communication technology and equipment; comprehensive hospital information technology and services. Rehabilitation Technology for Disabled Exhibition Area: Nursing equipment; nursing products; communication technology; mobile nursing; nursing services; medical technology; orthopedic technology; outpatient nursing; physiotherapy; prosthetics; services; ergotherapy; communication technology; wheelchairs. Pharmaceutical Exhibition Area: Prescription drugs; traditional Chinese medicines; western medicines; antibiotics; powdered injections; infusions; tablets; ointments; capsules; various new drugs; specialty drugs; national protected traditional Chinese medicine varieties; national basic medical insurance drugs; pharmaceutical raw materials; various intermediates; biochemical reagents and vaccines; various biological products. Dental Exhibition Area: Dental instruments and equipment; dental ...
- Source: drugdu
- 138
- November 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.